- Home
- VAPE vs MYNZ Comparison
VAPE vs MYNZ Comparison
Compare VAPE & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VAPE
- MYNZ
- Stock Information
- Founded
- VAPE N/A
- MYNZ 2021
- Country
- VAPE United States
- MYNZ Germany
- Employees
- VAPE N/A
- MYNZ N/A
- Industry
- VAPE
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- VAPE
- MYNZ Health Care
- Exchange
- VAPE NYSE
- MYNZ Nasdaq
- Market Cap
- VAPE 6.0M
- MYNZ 7.6M
- IPO Year
- VAPE N/A
- MYNZ 2021
- Fundamental
- Price
- VAPE $35.49
- MYNZ $1.84
- Analyst Decision
- VAPE
- MYNZ Buy
- Analyst Count
- VAPE 0
- MYNZ 2
- Target Price
- VAPE N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- VAPE 805.6K
- MYNZ 184.8K
- Earning Date
- VAPE 08-13-2025
- MYNZ 08-05-2025
- Dividend Yield
- VAPE N/A
- MYNZ N/A
- EPS Growth
- VAPE N/A
- MYNZ N/A
- EPS
- VAPE N/A
- MYNZ N/A
- Revenue
- VAPE $3,478,254.00
- MYNZ $893,991.00
- Revenue This Year
- VAPE N/A
- MYNZ $26.06
- Revenue Next Year
- VAPE N/A
- MYNZ $4.97
- P/E Ratio
- VAPE N/A
- MYNZ N/A
- Revenue Growth
- VAPE 10.08
- MYNZ N/A
- 52 Week Low
- VAPE $5.60
- MYNZ $1.34
- 52 Week High
- VAPE $82.88
- MYNZ $19.00
- Technical
- Relative Strength Index (RSI)
- VAPE N/A
- MYNZ 48.65
- Support Level
- VAPE N/A
- MYNZ $1.89
- Resistance Level
- VAPE N/A
- MYNZ $2.07
- Average True Range (ATR)
- VAPE 0.00
- MYNZ 0.20
- MACD
- VAPE 0.00
- MYNZ 0.01
- Stochastic Oscillator
- VAPE 0.00
- MYNZ 34.92
About VAPE CEA INDUSTRIES INC
CEA Industries Inc through its subsidiary is focused on selling environmental control and other technologies and services to the Controlled Environment Agriculture ("CEA") industry. The company provides integrated mechanical, electrical, and plumbing ("MEP") engineering design, proprietary and curated environmental control equipment, and automation offerings that serve the CEA industry. The Company has one operating segment that is dedicated to the manufacture and sale of its products.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.